[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335304-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335304-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-protein-based-prognostic-signature-linked-to-immunotherapeutic-efficiency-in-ovarian-cancer","Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer","","Personalized medicine in ovarian cancer remains difficult because tumors vary substantially and immune microenvironments are complex, especially in the immunotherapy era. Progress is hindered by the lack of dependable biomarkers that indicate which patients will benefit. Conventional clinicopathological factors provide limited prognostic value, while multi-omics profiling can clarify tumor–immune interactions. This study integrates individual proteomic and transcriptomic profiles to build a protein-based signature for prognosis and for distinguishing immunotherapy response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-protein-based-prognostic-signature-linked-to-immunotherapeutic-efficiency-in-ovarian-cancer/335304/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-protein-based-prognostic-signature-linked-to-immunotherapeutic-efficiency-in-ovarian-cancer/335304.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study aim to solve in ovarian cancer immunotherapy?","Question",{"text":63,"@type":64},"The study addresses the unmet need for reliable biomarkers that identify patients who will benefit from immunotherapy despite ovarian cancer heterogeneity and complex immune microenvironments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the protein-based prognostic signature developed?",{"text":68,"@type":64},"Patients are clustered using immune-related gene sets, immune-related proteins are identified, and a multistage workflow using LASSO and Cox regression yields a signature containing five immune-related proteins.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main findings regarding prognosis and immune features?",{"text":72,"@type":64},"The signature is validated in a cohort of 377 patients and outperforms conventional clinicopathological factors. High-risk patients show poorer overall survival and distinct immune landscapes, including higher CD8 T-cell infiltration and patterns linked to immunosuppression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335304,1790016374,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Chen et al. Journal of Ovarian Research (2024) 17:190 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-024-01518-w](https://doi.org/10.1186/s13048-024-01518-w)  \nRESEARCH Open Access  \nNovel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer  \nShuo-Fu Chen 1, Liang-Yun Wang2, Yi-Sian Lin3 and Cho-Yi Chen2,4*  \nAbstract  \nBackground Personalized medicine remains an unmet need in ovarian cancer due to its heterogeneous nature and complex immune microenvironments, which has gained increasing attention in the era of immunotherapy. A key obstacle is the lack of reliable biomarkers to identify patients who would benefit significantly from the therapy. While conventional clinicopathological factors have exhibited limited efficacy as prognostic indicators in ovarian cancer, multi-omics profiling presents a promising avenue for comprehending the interplay between the tumor and immune components. Here we aimed to leverage the individual proteomic and transcriptomic profiles of ovarian cancer patients to develop an effective protein-based signature capable of prognostication and distinguishing responses to immunotherapy.  \nMethods The workflow was demonstrated based on the Reverse Phase Protein Array (RPPA) and RNA-sequencing profiles of ovarian cancer patients from The Cancer Genome Atlas (TCGA) . The algorithm began by clustering patients using immune-related gene sets, which allowed us to identify immune-related proteins of interest. Next, a multistage process involving LASSO and Cox regression was employed to distill a prognostic signature encompassing five immune-related proteins. Based on the signature, we subsequently calculated the risk score for each patient and evaluated its prognostic performance by comparing this model with conventional clinicopathological characteristics. Results We developed and validated a protein-based prognostic signature in a cohort of 377 ovarian cancer patients. The risk signature outperformed conventional clinicopathological factors, such as age, grade, stage, microsatellite instability (MSI), and homologous recombination deficiency (HRD) status, in terms of prognoses. Patients in the high-risk group had significantly unfavorable overall survival (p \u003C 0. 001) . Moreover, our signature effectively stratified patients into subgroups with distinct immune landscapes. The high-risk group exhibited higher levels of CD8 T-cell infiltration and a potentially greater proportion of immunotherapy responders. The co-activation oftheTGF-β pathway and cancer-associated fibroblasts could impair the ability of cytotoxic T cells to eliminate cancer cells, leading to poor outcomes in the high-risk group.  \nConclusions The protein-based signature not only aids in evaluating the prognosis but also provides valuable insights into the tumor immune microenvironments in ovarian cancer. Together our findings highlight the  \n*Correspondence:  \nCho-Yi Chen [choyichen@nycu.edu.tw](choyichen@nycu.edu.tw)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024, corrected publication 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecom](http://creativecom)[mons.org/l](mons.o","cbCaidpl990pzEpi","https://ap.wps.com/l/cbCaidpl990pzEpi","pdf",11016395,18,"English","# Abstract\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What problem does the study aim to solve in ovarian cancer immunotherapy?\",\"answer\":\"The study addresses the unmet need for reliable biomarkers that identify patients who will benefit from immunotherapy despite ovarian cancer heterogeneity and complex immune microenvironments.\"},{\"question\":\"How is the protein-based prognostic signature developed?\",\"answer\":\"Patients are clustered using immune-related gene sets, immune-related proteins are identified, and a multistage workflow using LASSO and Cox regression yields a signature containing five immune-related proteins.\"},{\"question\":\"What are the main findings regarding prognosis and immune features?\",\"answer\":\"The signature is validated in a cohort of 377 patients and outperforms conventional clinicopathological factors. High-risk patients show poorer overall survival and distinct immune landscapes, including higher CD8 T-cell infiltration and patterns linked to immunosuppression.\"}]","Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer | PDF",1790010461,45]